Synthetic and Plant Cannabinoids Impacts in Mice | cannabisMD

Synthetic and Plant Cannabinoids Impacts in Mice

Synthetic and Plant Cannabinoids Impacts in Mice; British Pharmacological Society

British Pharmacological Society

Synthetic and plant‐derived cannabinoid receptor antagonists show hypophagic properties in fasted and non‐fasted mice

Cannabinoids are located in the marijuana plant (cannabis sativa) and are seen to be quite good at managing pain symptoms such as arthritis and obesity. Cannabinoids are a group of complex chemical compounds that happen naturally in the body and work on primary cannabinoid receptors in cells that controls neurotransmitter release in the brain. Cannabinoids for these receptors involve the endocannabinoid network, that are made in the body by humans, the plant cannabinoids in marijuana and some other plants, and synthetic cannabinoids. The main endogenous cannabinoid is the plant cannabinoid tetrahydrocannabinol (THC), the main psychotropic compound in marijuana. Cannabidiol (CBD) is another main part of the plant and gives off a non psychotic effect. Cannabinoids have a therapeutic possibility in humans and animals, however they are yet to be looked into in more depth to cure a wide range of human and animal diseases. This paper will look at synthetic and plant cannabinoids in the treatment of obese mice.

Main Points

  • Cannabinoids in the treatment of obesity
  • Cannabinoids therapeutic potential

Cannabinoids in the treatment of obesity

Obesity is a serious health complication in first world countries and knowing the central nervous actions outlining food‐wanting behaviour and accolade are at the nose of medical experiments. Cannabinoid receptors have seen to be an effective site to prevent hunger and weight increase by their pharmacological allaying. An average immediate approach and a normal system with free‐feeding animals were applied to test the feeding actions of mice cured with the Cannabinoid receptor 1 antagonist AM251. Similarly, the impacts of the plant cannabinoid THC, which acts like a Cannabinoid receptor 1 antagonist, were also evaluated in free‐feeding animals. AM251 seemed to prevent the rate of food intake and weight gain in starved and non‐starved animals. The prevention of food intake by AM251 durated for six to eight hours when applied precisely, and was flowing when induced for four consecutive days. Pure THC also made hypophagia occur and weight decreasing at very low concentrations. However, a potent THC solution was not able to prevent food intake and weight increasing, potentially due to remnants of THC in the solution This THC impact was fought by the co‐dosing of CBD.

Cannabinoids therapeutic potential

The results of this study potently indicates the long‐term evaluation network is a sensitive and obesity‐relevant instrument, and the plant cannabinoid THC is a normal chemical with hypophagic abilities and a plausible therapeutic for obesity. Overall, these results illustrate the hypophagic impacts of AM251 in a normal assessed procedural observation network. The plant cannabinoid THC which also acts like a Cannabinoid receptor 1 antagonist brought on by hypophagia and a decreasing in body weight at low administrative concentrations. The limitation of any decreasing of food intake and weight gain with the THC rich solution could be a result of residual THC within the solution.

Riedel_et_al-2009-British_Journal_of_Pharmacology

Leave a Reply

Your email address will not be published. Required fields are marked *